Invivyd (IVVD) Corporate Presentation summary

Strategic vision and pipeline

• Focused on developing best-in-class antibody therapies for multiple viral threats, including COVID, Long COVID, RSV, and measles, with a broad and rapidly advancing pipeline.

• Proprietary discovery platform leverages analytics and antigen binding to target mutable viral epitopes, aiming for superior monoclonal antibodies (mAbs).

• Technology designed for both long and short half-life applications, addressing prevention and treatment needs across various infectious diseases.

COVID-19 market and unmet needs

• COVID is recognized as a systemic, not just respiratory, disease with ongoing complications, including neurodevelopmental and cardiovascular effects.

• Significant portion of the population remains unvaccinated due to concerns about side effects, distrust, and lack of perceived risk, highlighting demand for alternatives.

• Current mRNA vaccines show declining efficacy over time, with only modest protection against hospitalization.

Monoclonal antibody innovation and clinical progress

• Monoclonal antibodies offer engineered, consistent high activity and can be designed to overcome human immune limitations.

• Antibodies such as pemivibart and VYD2311 demonstrate robust durability and stability against CDC-tracked variants.

• VYD2311 is advancing through pivotal clinical trials, including safety, efficacy, and combination studies with mRNA vaccines.

• Commercial infrastructure is scaling to support broad market access, with PEMGARDA establishing a strong foundation.